Tryptamine Therapeutics Ltd
TYP
Company Profile
Business description
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Contact
C/o Bio101 Financial Advisory Pty Ltd
697 Burke Road, Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920475
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
50
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,599.40 | 56.50 | 0.66% |
| CAC 40 | 7,489.35 | 43.66 | 0.59% |
| DAX 40 | 20,340.57 | 124.38 | 0.62% |
| Dow JONES (US) | 42,528.36 | 178.20 | -0.42% |
| FTSE 100 | 8,245.28 | 4.38 | -0.05% |
| HKSE | 19,267.60 | 179.98 | -0.93% |
| NASDAQ | 19,489.68 | 375.30 | -1.89% |
| Nikkei 225 | 39,981.06 | 102.24 | -0.26% |
| NZX 50 Index | 13,043.11 | 1.05 | 0.01% |
| S&P 500 | 5,909.03 | 66.35 | -1.11% |
| S&P/ASX 200 | 8,349.10 | 64.00 | 0.77% |
| SSE Composite Index | 3,230.17 | 0.52 | 0.02% |